India, Aug. 5 -- Sight Sciences, Inc. (SGHT), an eye care technology company, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the OMNI Ultra Surgical System, a handheld, single-use therapeutic device for minimally invasive glaucoma surgery (MIGS).
The OMNI Ultra Surgical System is indicated for canaloplasty (microcatheterization and viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of the trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
The key features of the device include implant-free intervention, circumferential canaloplasty in a single pass, TruSync Plus technology for controlled viscodilation during advancement and ...